DOES ADHERENCE TO INHALED THERAPY CHANGE FOLLOWING INITIATION OF MEPOLIZUMAB IN THE TREATMENT OF SEVERE ASTHMA?

被引：0
|
作者：
d'Ancona, G. [1 ]
Liu, B. [2 ]
Wei, L. [2 ]
Green, L. [1 ]
Fernandes, M. [1 ]
Roxas, C. [1 ]
Osman, L. [1 ]
Kavanagh, J. [1 ]
Jackson, D. J. [1 ]
Kent, B. D. [1 ]
机构：
[1] Guys Hosp, London, England
[2] UCL Sch Pharm, London, England
来源：
THORAX | 2018年 / 73卷
关键词：
D O I：
10.1136/thorax-2018-212555.87
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
S81
引用
收藏
页码：A50 / A51
页数：2
相关论文
共 50 条
  • [1] Does Adherence to Inhaled Therapy Change Following Initiation of Mepolizumab in the Treatment of Severe Asthma
    d'Ancona, G.
    Green, L.
    Fernandes, M.
    Bolton, M.
    Roxas, C.
    Osman, L.
    Lyons, E.
    Jackson, D. J.
    Kent, B. D.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [2] DOES ADHERENCE TO ICS/LABA THERAPY CHANGE FOLLOWING INITIATION OF BENRALIZUMAB IN THE TREATMENT OF SEVERE ASTHMA AND DOES THIS AFFECT OUTCOME?
    d'Ancona, G.
    Bains, S.
    Bakrania, P.
    Green, L.
    Fernandes, M.
    Roxas, C.
    Thomson, L.
    Osman, L.
    Stewart-Knight, K.
    Dhariwal, J.
    Nanzer, A. M.
    Kavanagh, J.
    Jackson, D. J.
    Kent, B. D.
    [J]. THORAX, 2019, 74 : A136 - A136
  • [3] Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma?
    d'Ancona, Grainne
    Green, Linda
    Fernandes, Mariana
    Roxas, Cris
    Osman, Leyla
    Stewart-Knight, Kirsten
    Kavanagh, Joanna
    Nanzer-Kelly, Alexandra
    Jackson, David
    Kent, Brian
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [4] DOES ADHERENCE TO INHALED THERAPY CHANGE FOLLOWING A PRESENTATION TO THE EMERGENCY DEPARTMENT AND A REVIEW IN ASTHMA CLINIC?
    Barnard, R.
    Fernandez, M.
    Green, L.
    Roxas, C.
    Whittock-Knott, A.
    Osman, L.
    Kavanagh, J.
    Jackson, D. J.
    Kent, B. D.
    d'Ancona, G. M.
    [J]. THORAX, 2018, 73 : A65 - A65
  • [5] Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma
    d'Ancona, Grainne
    Kavanagh, Joanne
    Roxas, Cris
    Green, Linda
    Fernandes, Mariana
    Thomson, Louise
    Dhariwal, Jaideep
    Nanzer, Alexandra M.
    Jackson, David J.
    Kent, Brian D.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2020, 55 (05)
  • [6] Adherence to inhaled corticosteroids and clinical outcomes following a year of benralizumab therapy for severe eosinophilic asthma
    D'Ancona, Grainne
    Kavanagh, Joanne E.
    Dhariwal, Jaideep
    Hearn, Andrew P.
    Roxas, Cris
    Fernandes, Mariana
    Green, Linda
    Thomson, Louise
    Nanzer, Alexandra M.
    Jackson, David J.
    Kent, Brian D.
    [J]. ALLERGY, 2021, 76 (07) : 2238 - 2241
  • [7] Severe Pediatric Asthma Therapy: Mepolizumab
    Ullmann, Nicola
    Peri, Francesca
    Florio, Olivia
    Porcaro, Federica
    Profeti, Elisa
    Onofri, Alessandro
    Cutrera, Renato
    [J]. FRONTIERS IN PEDIATRICS, 2022, 10
  • [8] Mepolizumab for the treatment of severe eosinophilic asthma
    Poulakos, Mara N.
    Cargill, Shawna M.
    Waineo, Melissa F.
    Wolford, Allen L., Jr.
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2017, 74 (13) : 963 - 969
  • [9] Mepolizumab in the treatment of severe eosinophilic asthma
    Fainardi, Valentina
    Pisi, Giovanna
    Chetta, Alfredo
    [J]. IMMUNOTHERAPY, 2016, 8 (01) : 27 - 34
  • [10] An evaluation of mepolizumab for the treatment of severe asthma
    Morjaria, Jaymin B.
    Emma, Rosalia
    Fuochi, Virginia
    Polosa, Riccardo
    Caruso, Massimo
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (06) : 491 - 500
12345